News
RSS feedFirst Large Real-World Study of Oregon's Licensed Psilocybin Services Published
Oregon Health & Science University researchers have published a 346-person observational study of the US state's licensed psilocybin service centres in JAMA Network Open.
Company Reports Positive Topline Results from Pivotal US Trial of LSD-Based Drug for Anxiety
US company Definium Therapeutics says its Phase 3 Voyage trial of DT120, an LSD-based drug candidate for generalised anxiety disorder, met its primary and key secondary endpoints.
MDMA-Assisted Therapy Application Resubmitted to US FDA, MAPS Says
MAPS says Resilient Pharmaceuticals has resubmitted its new drug application for MDMA-assisted therapy for PTSD to the US FDA, two years after the agency declined to approve it.
First Publicly Funded UK Trial of Psilocybin for Treatment-Resistant Depression Publishes Results
King's College London researchers have published results from PsiDeR, a 60-person NHS randomised controlled trial of a single psilocybin dose in treatment-resistant depression.
Compass Pathways Targets Late-2026 FDA Filing and 2027 US Launch for Its Psilocybin Product
In results announced 5 August, Compass Pathways said it expects to complete its FDA submission for COMP360 psilocybin in late 2026, with a potential US launch in the first half of 2027.
Mind Medicine Australia Urges TGA to Reverse Interim Decision on Psilocybin for End-of-Life Distress
The advocacy charity has publicly released an objection to the TGA's interim decision declining to extend psilocybin access to existential distress in terminally ill patients.
US Pilot Trial of Psilocybin-Assisted Therapy for Veterans' PTSD Reports Early Results
Ohio State University researchers have published results from a 12-person open-label pilot trial of psilocybin-assisted therapy in veterans with severe treatment-resistant PTSD.
US Doctor Charged With Manslaughter Over Death at Unregulated MDMA–Ketamine Retreat
A Florida case involving a fatal 'Heart Protocol' ceremony is a stark reminder of why vetting matters before attending any psychedelic retreat, at home or abroad.
Eli Lilly to Acquire Psychedelic Developer AtaiBeckley in Deal Worth up to US$3.8 Billion
The world's largest pharmaceutical company has agreed to buy AtaiBeckley, developer of an intranasal 5-MeO-DMT candidate for treatment-resistant depression.
US FDA Finalises Psychedelic Trial Guidance and Sets September Public Hearing
The US drug regulator has finalised its guidance for psychedelic clinical trials and will hold a public hearing on supervised therapeutic use in September 2026.
TGA Relaxes In-Room Requirements for Authorised Prescriber Sessions
A 2026 regulatory update changes who must be physically present during MDMA/psilocybin dosing sessions under Australia's Authorised Prescriber scheme.
Synthesis Institute Resumes Bookings After 2023 Financial Collapse
The Netherlands-based psilocybin retreat operator, which underwent a well-documented 2023 collapse, has 2026 retreat dates live on its booking system.
Oregon's HB 2387 Expands Facilitator Protections From 1 January 2026
A new Oregon law allows licensed healthcare providers who are also psilocybin facilitators to deliver services without professional-board discipline risk.
Clarion Clinics Rebrands as Mind Medicine Australia Clinic
Melbourne's Clarion Clinics, one of Australia's first dedicated psychedelic-assisted therapy clinics, now operates under a new name.